Search academic texts

Information × Registration Number 0224U001520, 0121U112326 , R & D reports Title Developing the algorythm for minimal residual disease diagnostics and immunological rehabilitation in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma after antineoplastic program therapy popup.stage_title Head Vyhovska Yaroslava I., д.мед.н.Masliak Zvenyslava V., д.мед.н. Registration Date 25-01-2024 Organization State institution "Institute of blood pathology and transfusion medicine of Nataional Academy of Medical scinces of Ukraine" popup.description2  This study included 78 patients with chronic lymphocytic leukemia (CLL) who were treated for the first time and for relapsed/refractory disease. In this group there were 32 females and 46 males, aged 45.9 - 90.0 years. In patients with complete clinical and hematological response (CR), the status of minimal residual disease (MRD) was assessed by multicolor cytometry. Ranking of the status of MRD was performed in 3 levels: "negative" from 0.0 % to 0.01 %, "close to negative" from 0.01 % to 0.1 % and "positive" status - from 0.1 % and above. Group with CR included 43 patients, namely 16 patients (37.21 %) with "negative" status of MRD, 3 (6.98 %) with "close to negative", and 15 (34.88 %) with "positive" status, 9 (20.93 %) patients were not tested. Therapy efficacy was studied depending on the number of line. In the 1st line of therapy, a "negative" status was found in 12 patients, after the 2 nd line of therapy - in 4 patients, and only in 2 patients MRD was negative after the 3rd line of therapy. In 3 patients MRD was negative after 4 or more lines of therapy. Among the 43 patients who achieved CR, 3 patients (6.98 %) died due to the COVID-19, and 2 had confirmed progression. The indicators of immunity in patients who received chemoimmunotherapy (CIT) were studied: proteinogram, serum level of immunoglobulin G. The level of Ig G ranged from 0.87 to 5.55 g/l. All examined patients had indications for replacement therapy with immunoglobulin G even without infectious and inflammatory changes. Complications developed in 78 % of patients, of which 2/3 had pneumonia of varying severity, and a 1/3 had herpes and/or fungal infection. It has been confirmed that CIT in CLL leads to immunosuppression and requires immunocorrection with immunoglobulin G. Product Description popup.authors Danysh Olha Yo Dorosh Lilia V Zadoretska Iryna V Knysh Nataliya V Lukavetskyy Les' M Miliashkevych Halyna B Matlan Volodymyr L Prymak Sofiya V Thir Hrystyna R Tsyapka Orest M popup.nrat_date 2024-01-25 Close